Thousands of Blood Cancer Patients Could Benefit From a New Drug Combination – The Institute of Cancer Research
The Institute of Cancer Research shared a post on LinkedIn:
“BREAKING
Thousands of blood cancer patients could benefit from a new drug combination.
Patients with B-cell lymphoma currently have varying responses to the drug tazemetostat.
Researchers at the ICR have found that the drug – which is approved for use in patients with one type of B-cell lymphoma – could work better when combined with another targeted drug, a DOT1L inhibitor.
They found that the combination could also work for patients with the most common type of B-cell lymphoma, affecting thousands of patients in the UK each year.
A DOT1L inhibitor drug is already in clinical trials, so the team hope the combination could benefit blood cancer patients sooner.
Our research is helping more people survive blood cancer.
Please make a regular gift today and support the vital work our scientists are carrying out to defeat cancer.
More posts featuring The Institute of Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023